MARKET

DXCM

DXCM

DexCom
NASDAQ

Real-time Quotes | Nasdaq Last Sale

391.69
+2.38
+0.61%
After Hours: 393.00 +1.31 +0.33% 19:55 09/21 EDT
OPEN
385.00
PREV CLOSE
389.31
HIGH
393.21
LOW
381.66
VOLUME
667.85K
TURNOVER
--
52 WEEK HIGH
456.23
52 WEEK LOW
145.23
MARKET CAP
37.50B
P/E (TTM)
179.26
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Tracking Ron Baron's BAMCO Portfolio - Q2 2020 Update
BAMCO’s 13F portfolio value increased from $20.41B to $27.66B this quarter.Ron Baron added ZoomInfo Tech and increased Zillow Group during the quarter.Their top five positions are at ~22% of the overall portfolio.
Seekingalpha · 12h ago
DexCom: Not Too Late To The Party
Current investors looking into buying DexCom may feel discouraged and late to the party, thinking that most of the returns to be made have already materialized.New patients are likely to commit to a recurring stream of cash flows, boosting the company's ARR, while profitability is also set to grow amid net income margins expanding.While current investors are unlikely to see explosive gains, they are not that late for considerable, possibly market-beating gains in the medium term.
Seekingalpha · 13h ago
How To Avoid The Noise And Invest For Long-Term Success
Let's face it, today's retail investor is bombarded with information, and parsing through what is useful and what is not can be challenging.Avoiding noise and executing under pressure are critical to investing success.I've been managing custom-built equity portfolios since 2012, and hope to engage with those on Seeking Alpha interested in long-term investment success.I will look to do this with the tools I've developed to manage portfolios.
Seekingalpha · 15h ago
DexCom: A Superior Business Model But Watch Out For Debt Level
DexCom produces continuous glucose monitoring devices.The stock price has increased steeply in the last one year, but a slight dip recently constitutes an opportunity for investors.The medical devices company has enjoyed double-digit growth and looks likely to continue when considering the business model.It has a high level of product differentiation compared with competitors but debt level is also higher.The stock has the potential to climb much higher.
Seekingalpha · 1d ago
DexCom Introduces Registry to Monitor Outcomes of G6 System
DexCom (DXCM) sets up registry to track outcomes of patients and healthcare professionals using CGM in hospitals.
Zacks · 3d ago
Do You Own The 10 Most Expensive Stocks Right Now?
Investor's Business Daily · 3d ago
Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic
Dexcom announces first-ever registry dedicated to tracking outcomes of in-hospital real-time CGM use in response to the COVID-19 pandemic
Business Wire · 5d ago
DexCom Highlights Registry Dedicated To Tracking Outcomes Of Patients, Healthcare Professionals Using CGM In Hospitals In Response To COVID-19 Pandemic
DexCom, Inc. ((
Benzinga · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DXCM stock price target is 475.06 with a high estimate of 540.00 and a low estimate of 400.00.
EPS
Institutional Holdings
Institutions: 863
Institutional Holdings: 100.43M
% Owned: 104.90%
Shares Outstanding: 95.74M
TypeInstitutionsShares
Increased
242
10.80M
New
242
1.34M
Decreased
220
11.54M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.45%
Healthcare Equipment & Supplies
-1.43%
Key Executives
Chairman/President/Chief Executive Officer/Director
Kevin Sayer
Chief Financial Officer/Chief Operating Officer
Quentin Blackford
Executive Vice President/Chief Technology Officer
Jake Leach
Executive Vice President
Donald Abbey
Executive Vice President
Andrew Balo
Executive Vice President
Richard Doubleday
Executive Vice President
Patrick Murphy
Executive Vice President
Steven Pacelli
Senior Vice President - Finance/Chief Accounting Officer
Jereme Sylvain
Senior Vice President
Jeffrey Moy
Senior Vice President
Shelly Selvaraj
Lead Director/Independent Director
Mark Foletta
Independent Director
Steven Altman
Independent Director
Nicholas Augustinos
Independent Director
Richard Collins
Independent Director
Karen Dahut
Independent Director
Bridgette Heller
Independent Director
Barbara Kahn
Independent Director
Jay Skyler
Independent Director
Eric Topol
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average DXCM stock price target is 475.06 with a high estimate of 540.00 and a low estimate of 400.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DXCM
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of DexCom, Inc. stock information, including NASDAQ:DXCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DXCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DXCM stock methods without spending real money on the virtual paper trading platform.